102 related articles for article (PubMed ID: 20418240)
1. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.
Buitenkamp TD; Mathôt RA; de Haas V; Pieters R; Zwaan CM
Haematologica; 2010 Jul; 95(7):1106-13. PubMed ID: 20418240
[TBL] [Abstract][Full Text] [Related]
2. Severe Methotrexate Toxicity Following a Capizzi Cycle in an Obese Adolescent With Acute Lymphoblastic Leukemia and Hepatic Steatosis.
Fischer JM; Lertkovit O; Howard SC; Assanasen C; Bleyer A
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e107-e110. PubMed ID: 37916829
[TBL] [Abstract][Full Text] [Related]
3. Clinico-radiological profile, management and follow-up of methotrexate induced neurotoxicity in children with acute lymphoblastic leukemia.
Dhariwal N; Roy Moulik N; Smriti V; Dhamne C; Chichra A; Srinivasan S; Narula G; Banavali S
Leuk Lymphoma; 2023 Dec; 64(12):1971-1980. PubMed ID: 37565568
[TBL] [Abstract][Full Text] [Related]
4. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.
Taylor ZL; Miller TP; Poweleit EA; DeGroote NP; Pommert L; Awoniyi O; Board SG; Ugboh N; Joshi V; Ambrosino N; Chavana A; Bernhardt MB; Schafer ES; O'Brien MM; Castellino SM; Ramsey LB
Clin Transl Sci; 2023 Nov; 16(11):2130-2143. PubMed ID: 37503924
[TBL] [Abstract][Full Text] [Related]
5. Epigenome-wide association study of acute lymphoblastic leukemia in children with Down syndrome.
Li S; Sok P; Xu K; Muskens IS; Elliott N; Myint SS; Pandey P; Hansen HM; Morimoto LM; Kang AY; Metayer C; Ma X; Mueller BA; Roy A; Roberts I; Rabin KR; Brown AL; Lupo PJ; Wiemels JL; de Smith AJ
Blood Adv; 2022 Jul; 6(14):4132-4136. PubMed ID: 35588500
[No Abstract] [Full Text] [Related]
6. All about Down syndrome ALL.
Gu Z; Izraeli S
Blood; 2023 Jul; 142(2):126-128. PubMed ID: 37440267
[No Abstract] [Full Text] [Related]
7. Reply to: "Severe Methotrexate Toxicity Following a Capizzi Cycle in an Obese Adolescent With Acute Lymphoblastic Leukemia and Hepatic Steatosis" Published January 2024.
Kanwar VS
J Pediatr Hematol Oncol; 2024 Mar; 46(2):112. PubMed ID: 38236990
[No Abstract] [Full Text] [Related]
8. From niche to blockbuster: a greater role for allopurinol in maintenance treatment of acute lymphoblastic leukemia.
Stanulla M
Haematologica; 2024 May; ():. PubMed ID: 38721742
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.
Garré ML; Relling MV; Kalwinsky D; Dodge R; Crom WR; Abromowitch M; Pui CH; Evans WE
J Pediatr; 1987 Oct; 111(4):606-12. PubMed ID: 2958611
[TBL] [Abstract][Full Text] [Related]
10. Unique clinical and biological features of leukemia in Down syndrome children.
Xavier AC; Ge Y; Taub J
Expert Rev Hematol; 2010 Apr; 3(2):175-86. PubMed ID: 21083461
[TBL] [Abstract][Full Text] [Related]
11. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
Maloney KW; Carroll WL; Carroll AJ; Devidas M; Borowitz MJ; Martin PL; Pullen J; Whitlock JA; Willman CL; Winick NJ; Camitta BM; Hunger SP
Blood; 2010 Aug; 116(7):1045-50. PubMed ID: 20442364
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome.
Kalwinsky DK; Raimondi SC; Bunin NJ; Fairclough D; Pui CH; Relling MV; Ribeiro R; Rivera GK
Am J Med Genet Suppl; 1990; 7():267-71. PubMed ID: 2149960
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review.
Cheng Y; Zhang Y; Zhang Y; Liu M; Zhao L
Eur J Clin Pharmacol; 2024 Jul; 80(7):965-982. PubMed ID: 38498098
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Model of Methotrexate in Brazilian Pediatric Patients with Acute Lymphoblastic Leukemia.
de Oliveira Henz P; Pinhatti AV; Gregianin LJ; Martins M; Curra M; de Araújo BV; Dalla Costa T
Pharm Res; 2023 Jul; 40(7):1777-1787. PubMed ID: 37291462
[TBL] [Abstract][Full Text] [Related]
15. Participation, challenges and needs in children with down syndrome during cancer treatment at hospital: a qualitative study of parents' experiences.
Bohnstedt C; Stenmarker M; Olersbacken L; Schmidt L; Larsen HB; Schmiegelow K; Hansson H
Front Rehabil Sci; 2023; 4():1099516. PubMed ID: 37180572
[TBL] [Abstract][Full Text] [Related]
16. Down Syndrome-Associated Arthritis (DA): Diagnostic and Management Challenges.
Jones JT; Kitchen J; Talib N
Pediatric Health Med Ther; 2022; 13():53-62. PubMed ID: 35311022
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Spectrum of Inflammatory Bowel Disease Associated With Specific Genetic Syndromes: Two Novel Pediatric Cases and a Systematic Review.
Gatti S; Gelzoni G; Catassi GN; Catassi C
Front Pediatr; 2021; 9():742830. PubMed ID: 34765575
[No Abstract] [Full Text] [Related]
18. Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia.
Gao X; Qian XW; Zhu XH; Yu Y; Miao H; Meng JH; Jiang JY; Wang HS; Zhai XW
Front Pharmacol; 2021; 12():701452. PubMed ID: 34326772
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
Sassen SDT; Mathôt RAA; Pieters R; de Haas V; Kaspers GJL; van den Bos C; Tissing WJE; Te Loo DMWW; Bierings MB; van der Sluis IM; Zwaan CM
Br J Haematol; 2021 Jul; 194(2):423-432. PubMed ID: 34060065
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes in children with Acute lymphoblastic leukemia with versus without coexisting Down's syndrome: A systematic review and meta-analysis.
Liao W; Liu Y
Medicine (Baltimore); 2020 Jul; 99(29):e21015. PubMed ID: 32702842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
